Table 2 Incidence of hypertriglyceridemia and univariate Cox regression analysis in each subgroup (n = 309, all male)
Events/patients | PYFU | Incidence per /100 PYFU (95% CI) | HR (95%CI) | P Value | Global P | |
|---|---|---|---|---|---|---|
Age (years) | ||||||
18 ~ 39 | 88/208 | 462.8 | 19.0 (15.4, 22.6) | Ref | 0.119 | |
≥ 40 | 52/101 | 203.9 | 25.5 (19.5, 31.5) | 1.313 (0.932–1.851) | 0.119 | |
BMI (kg/m2) a | ||||||
18.5 ~ 23.9 | 80/201 | 462.6 | 17.3 (13.8, 20.7) | Ref | 0.004 | |
≤ 18.4 | 9/23 | 49.9 | 18.0 (7.4, 28.7) | 1.068 (0.536–2.129) | 0.851 | |
≥ 24.0 | 50/83 | 151.3 | 33.1 (25.6, 40.6) | 1.817 (1.275–2.589) | 0.001 | |
Mode of HIV acquisition b | ||||||
Hetero | 22/48 | 98.1 | 22.4 (14.2, 30.7) | Ref | 0.918 | |
MSM | 113/243 | 525.5 | 21.5 (18.0, 25.0) | 0.956 (0.605–1.509) | 0.845 | |
Other | 5/13 | 27.9 | 17.9 (3.7, 32.1) | 0.815 (0.309–2.154) | 0.680 | |
Degree of education c | ||||||
High school and below | 57/126 | 266.3 | 21.4 (16.5, 26.3) | Ref | 0.509 | |
University and above | 45/106 | 244.6 | 18.4 (13.5, 23.3) | 0.876 (0.592–1.297) | 0.509 | |
CD4 cell count (cells/μL) | ||||||
≥ 350 | 53/115 | 248.3 | 21.3 (16.2, 26.4) | Ref | 0.021 | |
200 ~ 349 | 43/114 | 270.0 | 15.9 (11.6, 20.3) | 0.758 (0.507–1.134) | 0.178 | |
< 200 | 44/80 | 148.3 | 29.7 (22.3, 37.0) | 1.376 (0.922–2.052) | 0.118 | |
CD8 cell count (cells/μL) | ||||||
≥ 1000 | 68/128 | 252.9 | 26.9 (21.4, 32.4) | Ref | 0.045 | |
500 ~ 999 | 59/145 | 330.7 | 17.8 (13.7, 22.0) | 0.673 (0.475–0.954) | 0.026 | |
< 500 | 13/36 | 83.1 | 15.6 (7.8, 23.5) | 0.599 (0.331–1.084) | 0.090 | |
CD4/CD8 ratio | ||||||
≥ 0.60 | 11/40 | 103.5 | 10.6 (4.7, 16.6) | Ref | 0.003 | |
0.20 ~ 0.59 | 83/187 | 417.1 | 19.9 (16.1, 23.7) | 1.799 (0.958–3.377) | 0.068 | |
< 0.20 | 46/82 | 146.1 | 31.5 (24.0, 39.0) | 2.803 (1.449–5.422) | 0.002 | |
HIV RNA (log10 copies/mL) | ||||||
< 4.00 | 21/63 | 158.9 | 13.2 (7.9, 18.5) | Ref | 0.058 | |
4.00 ~ 4.99 | 66/144 | 303.3 | 21.8 (17.1, 26.4) | 1.562 (0.956–2.553) | 0.075 | |
≥ 5.00 | 53/102 | 204.5 | 25.9 (19.9, 31.9) | 1.850 (1.116–3.068) | 0.017 | |
ALT(U/L) | ||||||
≤ 50 (1.25 ULN) | 131/289 | 624.0 | 21.0 (17.8, 24.2) | Ref | 0.963 | |
> 50 (1.25 ULN) | 9/20 | 42.7 | 21.1 (8.9, 33.3) | 1.016 (0.517–1.997) | 0.963 | |
Plasma glucose (mmol/L) | ||||||
< 6.1 | 119/267 | 577.9 | 20.6 (17.3, 23.9) | Ref | 0.589 | |
≥ 6.1 | 21/42 | 88.8 | 23.7 (14.8, 32.5) | 1.136 (0.714–1.808) | 0.589 | |
TC (mmol/L) d | ||||||
< 5.2 | 134/294 | 633.7 | 21.1 (18.0, 24.3) | Ref | 0.871 | |
≥ 5.2 | 6/14 | 30.2 | 19.9 (5.6, 34.1) | 0.934 (0.412–2.117) | 0.871 | |
TG borderline high | ||||||
No | 115/280 | 636.6 | 18.1 (15.1, 21.1) | Ref | < 0.001 | |
Yes | 25/29 | 30.1 | 83.1 (69.7, 96.5) | 3.948 (2.546–6.122) | < 0.001 | |
cART regimen | ||||||
3TC + TDF + EFV | 85/238 | 557.8 | 15.2 (12.3, 18.2) | Ref | < 0.001 | |
3TC + AZT + EFV | 18/22 | 33.9 | 53.1 (36.3, 69.9) | 3.048 (1.827–5.084) | < 0.001 | |
3TC + TDF + LPV/r | 24/31 | 39.4 | 60.9 (45.7, 76.1) | 3.497 (2.213–5.527) | < 0.001 | |
Other regimens | 13/18 | 35.6 | 36.5 (20.7, 52.4) | 2.276 (1.269–4.083) | 0.006 | |
Overall | 140/309 | 666.7 | 21.0 (17.9, 24.1) | |||